Bước đầu ứng dụng phác đồ Hyper-CVAD kết hợp với Imatinib Mesylate điều trị bạch cầu cấp dòng Lympho PH (+)

Objectives: To report the efficacy and safety of imatinib plus Hyper-CVAD chemotherapy regimen in the treatment of patients with ph chromosome positive acute lymphocytic leukemia (Ph(+)ALL). Method and patients: Adult Ph(+)ALL patient was treated with imatinib plus Hyper-CVAD at hospital since December 2009 to January 2012. Results: Among 07 patients on chemotherapy, their average age was 36 years, the total response rate 100 percent following induction chemotherapy and the median overall survival 22.4 + or - 3 months, disease free survival 16.4 + or - 2 months. Conclusions: Imatinib plus Hyper-CVAD chemotherapy regimen is associated with significantly improved survival rates.